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Ⅰ．Introduction
 Osteonecrosis of the femoral head （ONFH） causes 
joint destruction after articular collapse, followed 
by impairment of quality of life due to hip pain and 
gait disturbances in young and active individuals［1］. 
Corticosteroid therapy is an influential factor in the 
development of ONFH; the incidence of ONFH was 
reported as 41% in adult systemic lupus erythematosus 
（SLE） patients［2］. In general, conservative treatment 
has little effect on the symptoms and surgical treatment 
often is required. The cumulative surgical frequency 
has been reported as 67% at 5 years after articular 
collapse in ONFH［3］. Preservation of the joint using 
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SUMMARY
Objectives: The aim was to evaluate the safety and efficacy of extracorporeal shock wave therapy 
（ESWT） for osteonecrosis of the femoral head.
Methods: This was a phase I clinical trial and prospective case-control study. Large osteonecrotic 
areas with advanced collapse were included. ESWT was applied from anterior to posterior with 5000 
impulses. Energy flux density was started at level one （0.03mJ/mm2） and advanced to level seven （0.36 
mJ/mm2）. A historical cohort was matched to this treatment group.
Results: ESWT and natural history groups each consisted of 28 hips. There were no obvious 
complications such as progression of osteonecrosis or neurovascular injury. ESWT group showed a 
gradual improvement in hip score and pain score, and these scores were significantly different than 
those of the natural history group at the end of treatment （p＝0.034 and 0.019, respectively）. The 
survival rate for total hip arthroplasty at two years was not significantly different between ESWT 
group and the natural history group （35.1% versus 24.7%, p＝0.749）. However, Cox regression 
analysis revealed that the type C2 hip was an independent and significant prognostic factor with an 8.6-
fold higher hazard ratio than type C1 （p＝0.004）.
Conclusions: ESWT showed safe and effective for osteonecrosis of the femoral head.
　Key words:  osteonecrosis of the femoral head, extracorporeal shock wave therapy
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regenerative medicine or femoral osteotomy has been 
proposed, but there are several limitations to these 
approaches［4-8］. Total hip arthroplasty （THA） is a 
promising surgical option although implant loosening 
requires revision surgery［9-10］. On the other hand, 
not all patients with osteonecrosis undergo surgery 
because of high risks associated with generally poor 
health related to the underlying disease. Therefore, it is 
important to establish safe and effective conservative 
treatment for ONFH.
 Extracorporeal shock wave therapy （ESWT） has 
been applied clinically to chronic painful musculoskeletal 
disorders［11-12］. ESWT induces degeneration of free 
nerve endings and sensory nerve fibers, followed by a 
decrease in the number of dorsal root ganglion neurons
［13-15］. As hip pain is caused by invasion of free nerve 
endings and sensory nerve fibers to the synovium［16］, 
we hypothesized that ESWT would provide pain relief 
from the collapsed femoral head in ONFH. The purpose 
of this study was to evaluate the safety and effectiveness 
of ESWT for ONFH.
Ⅱ．Patients and Methods
 The protocol for this phase I clinical trial and 
prospective case-control study was approved by the 
institutional review board and the participants gave 
written informed consent （University Hospital Medical 
Information Network, UMIN000020197）. The primary 
end point was to confirm safety and the secondary end 
point was to determine effectiveness.
 Patients with ONFH diagnosed by the classification 
of the Japanese Ministry of Health, Labor and Welfare 
（JMHLW）［17-18］, with large necrotic areas of type C1 
or C2, and with advanced collapse at stage 3B or 4 were 
included. It was reasonable ethically to study safety in 
these patients because they were, in principal, candidates 
for THA. In case of therapeutic failure, THA would 
be an acceptable salvage procedure. Exclusion criteria 
included patients with skeletal immaturity, previous 
or current infections, unfavorable skin conditions, or 
patients with hemorrhagic diathesis. The JMHWL 
classification was used to categorize lesion size and 
stage for articular collapse. A type A lesion occupies the 
medial one-third or less of the weight-bearing portion 
of the femoral head; a type B lesion occupies the medial 
two-thirds or less of the weight-bearing portion; a type 
C1 lesion occupies more than the medial two-thirds of 
the weight-bearing portion of the femoral head but does 
not extend laterally to the acetabular edge; and a type C2 
lesion extends laterally to the acetabular edge. Stage 1 is 
defined by normal findings on radiograph, but specific 
findings on magnetic resonance imaging （MRI）, a bone 
scan, or by histology; stage 2 is defined by demarcating 
sclerosis without collapse of the femoral head; stage 3A 
involves collapse of the femoral head less than 3mm in 
diameter; stage 3B involves collapse of the femoral head 
more than 3mm in diameter; and stage 4 is defined by 
osteoarthritic changes with joint space narrowing. 
 From August 2010 to September 2012, ESWT was 
performed after informed consent for all the participants 
in the shock wave group. A historical cohort of patients 
with ONFH from the same institution was matched 
to this treatment group by age, gender, etiology, and 
the type and stage classification of JMHLW. ESWT 
and natural history groups each consisted of 28 hips. 
Sensitivity analysis and power analysis could not be 
performed because there were no case-control studies 
in the previous literature. Julious［19］ recommended 
a sample size of 12 per group for a pilot study when 
there is no prior information on which to base a sample 
size. The sample size of 28 per group was based on the 
number of new patients annually （20-30 patients/year） 
in our hospital. ESWT was administered with Dornier 
EposTM （Dornier, Germany）, which generates a shock 
wave by electromagnetic induction. The junctional 
zone between the osteonecrotic and viable bone of 
the femoral head was identified radiologically using 
an image intensifier. One point within the junctional 
zone was chosen with a metallic pin under the image 
intensifier, and marked on the skin in the groin. The 
treatment was performed on a bed with the patient in 
the supine position in the outpatient clinic. Patients 
were awake without any anesthesia so that they could 
comment on whether the shock wave was reproducing 
their hip pain. The femoral artery was palpated and 
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protected from direct contact with the shock wave tube 
during the course of treatment. Ultrasound jelly was 
used on the skin in contact with the shock wave tube. 
Shock waves were applied from anterior to posterior 
with 5000 impulses at a rate of 240 impulses/min with 
a 4×25mm focus area. Energy flux density was started 
at level one （0.03mJ/mm2） and advanced as tolerated to 
level seven （0.36 mJ/mm2）. If pain from osteonecrosis 
was not reproduced by the shock wave, the shock wave 
tube was moved to find a point that reproduced the pain 
of osteonecrosis. ESWT was applied three times every 
one to two months. The follow-up period was two years.
Statistical Analysis
 Outcome measures were assessed by hip score 
using the Japanese Orthopaedic Association （JOA）
［20］, PainDETECT （PD）［21］, Visual Analogue Scale 
（VAS）, total energy of ESWT, and the progression of 
femoral head collapse. The Fisher exact probability test 
was calculated for gender difference, underlying disease 
（SLE versus non-SLE） and JMHLW classification 
using IBM SPSS Statistics 16.0 （Chicago, Illinois）. 
Pearson’s χ2 test was done for etiology （Steroidal, 
alcoholic, or “idiopathic”）. The Mann-Whitney U test 
was done for age, JOA hip score, PD score, and VAS. 
Friedman test was calculated for parameters at initial 
examination, the first, the second, and the third ESWT. 
The Kaplan-Meier method with log rank test and Cox 
regression analysis were calculated for the final end 
point of total hip arthroplasty. A p-value＜0.05 was 
considered significant.
Ⅲ．Results
 ESWT and natural history groups each consisted 
of 28 hips. Gender, age, etiology, underlying disease, 
classification of osteonecrosis, use of non-steroidal 
anti-inflammatory drugs, steroid dosage, duration after 
articular collapse, initial PD score and initial VAS were 
not significantly different between groups at the start 
of therapy （Table 1）. The initial JOA hip score was 
significantly worse in ESWT group than in the natural 
history group （41.9 points versus 54.6 points, p＝
0.012）. 
 There were no obvious complications such as rapid 
progression towards collapse of the osteonecrotic lesion 
or neurovascular injury after ESWT at the two-year 
follow up.
 ESWT group showed a gradual improvement 
in JOA hip score and VAS, and these scores were 
Table 1　Patient characteristics
Shock wave group （n＝28） Natural history group （n＝28） p values
Gender （male: female） 6:22 6:22 1.000*1
Age, years 47.4 （15.9） 50.1 （16.2） 0.528*2
Etiology （Steroidal: alcoholic:“idiopathic”） 25:2:1 25:2:1 1.000*3
Underlying disease （SLE: non-SLE） 15:13 10:18 0.282*1
JMHLW type classiﬁcation （C1: C2） 5:23 5:23 1.000*1
JMHLW stage classiﬁcation （3B: 4） 14:14 14:14 1.000*1
NSAIDs usage 21 （75%） 20 （71%） 0.999*2
Maximum steroid dosage （mg/day） 47 （24） 45 （24） 0.673*2
Minimum steroid dosage （mg/day） 6 （4） 5 （5） 0.199*2
Initial JOA hip score 41.9 （16.6） 54.6 （15.8） 0.012*2
Initial PD score 9.3 （4.9） 9.9 （4.6） 0.532*2
Initial VAS now 58.9 （24.6） 65.6 （19.4） 0.278*2
Duration after articular collapse （months） 29 （55） 22 （51） 0.619*2
Mean （standard deviation）
*1 Fisher exact probability test, *2 Mann-Whitney U test, *3 Pearson’s χ2 test
SLE: systemic lupus erythematosus, JMHLW: Japanese Ministry of Health, Labor and Welfare, JOA: Japanese Orthopaedic 
Association, PD: Pain Detect, VAS: Visual Analogue Scale （mm）, NSAIDs: non-steroidal anti-inflammatory drugs
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significantly different than those of the natural history 
group at the end of treatment （p＝0.034 and 0.019, 
respectively, Table 2）. The focal energy of the shock 
wave significantly increased over the course of the 
treatment （p＝0.026）. On the other hand, the JOA hip 
score deteriorated in the natural history group （p＝
0.011, Table 3）. Thus, the amount of change in the 
JOA hip score that occurred within ESWT and natural 
history groups was significantly different by the end 
of treatment （＋9.1 points versus －10.5 points, p＝
0.001）. The groups also differed significantly on the 
VAS score （－9.0 points versus ＋3.6 points, p＝
Table 2　Time course of shock wave group1
Initial First ESWT3 Second ESWT Third ESWT p values2
JOA hip score
41.9
（16.6）
49.7
（18.3）
52.9
（19.2）
52.5
（19.5）
0.034
PD score
9.3
（4.9）
8.9
（4.9）
9.6
（6.3）
9.2
（5.8）
0.976
VAS
58.9
（24.6）
40.3
（21.5）
42.8
（29.1）
44.7
（26.3）
0.019
Total
focal energy
（mJ/mm2）
－
1334.5
（482.6）
1432.0
（440.6）
1563.2
（344.9）
0.026
1 Mean （standard deviation）
2 Friedman test
3 ESWT: extracorporeal shock wave therapy
Table 3　Outcome of the natural history group1
Initial Final p values2
JOA score 54.6 （15.8） 44.1 （17.1） 0.011
PD score 9.9 （4.6） 10.6 （5.6） 0.131
VAS 65.6 （19.4） 69.3 （23.7） 0.194
1 Mean （standard deviation）
2 Mann-Whitney U test
Fig. 1　 Survivorship of shock wave and natural history 
groups
　When the end point was total hip arthroplasty, survival 
at one year was 42.9% in the shock wave group and 45.1% 
in the natural history group; survival at two years was 
35.1% in the shock wave group and 24.7% in the natural 
history group, without a significant difference （Kaplan-
Meier and log rank test, p＝0.749）.
Fig. 2　 Survivorship of type C1 and type C2 hips by 
JMHLW classification
　When the end point was total hip arthroplasty, survival 
at one year was 100% in type C1 and 33.8% in type C2; 
survival at two years was 88.9% in type C1 and 18.0% in 
type C2, with a significant difference （Kaplan-Meier and 
log rank test, p＝0.001）.
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offers several important advantages over conventional 
surgical treatment: it is a noninvasive treatment with a 
substantially reduced incidence of complications, and 
it does not make the technique of THA difficult, if it 
becomes necessary, because skeletal alignment has not 
been altered. 
 Ludwig et al.［22］reported favorable results with 
ESWT in which 14 of 21 patients improved in pain 
and hip score over one year, but one-third （7 patients） 
returned to their previous symptoms. Wang et al.［23］
reported that 79% of the hips were improved, 10% 
were unchanged, and 10% were worse with ESWT in 
a prospective study. Wang’s group performed ESWT 
under general anesthesia with 6000 impulses of 0.62 mJ/
mm2 energy flux density （total dose: 3720 mJ/mm2） at 
one time. In Japan, the maximum energy flux density is 
limited by law to 0.36 mJ/mm2. In our study, the energy 
flux density began at 0.03mJ/mm2 and increased to 0.36 
mJ/mm2 without anesthesia, using three treatments of 
5000 pulses each. The difference in protocol may be 
one reason our results are not as positive as Wang’s. 
Hausdorf et al.［24］showed that 49.2% of the shock 
wave pressure occurred 10 mm inside the femoral head, 
and the pressure increased with energy. Therefore high-
energy shock waves may be more effective to regenerate 
bone.
 Another factor may be the extent of osteonecrosis. 
Ludwig et al.［22］indicated ESWT was successful 
for the early stage osteonecrosis. Vulpiani et al.［25］
reported patients at stages 1 or 2 achieved significantly 
better results than patients at stage 3 at all time points. 
At a minimum two-year follow up, 10 of the 15 stage 
3 patients （67%） received arthroplasty, whereas stage 
1 and 2 lesions were unchanged on radiographs and on 
magnetic resonance images. Wang et al.［26］reported 
total hip replacement after ESWT in 12% of patients 
with SLE at a minimum two-year follow up, but 
they did not include the patients at stage 4. Our study 
included only advanced or end stage osteonecrosis 
patients and found the prognosis at stage 4 to be poor. 
We believe this is another reason for our poor outcome.
 Type C2  hips classified using the JMHLW 
classification are an independent prognostic indicator 
0.021）. 
 The survival rate for THA was not significantly 
different between ESWT group and the natural history 
group （p＝0.749, Figure 1）. However, the survival rate 
was significantly better in type C1 than in type C2 hips 
by the JMHLW classification （p＝0.001, Figure 2）. 
The survival rate also was significantly better in stage 
3B than in stage 4 using this classification （p＝0.027, 
Figure 3）. Cox regression analysis revealed that the type 
C2 hip was an independent and significant prognostic 
factor for THA with an 8.6 fold higher hazard ratio than 
type C1 （p＝0.004）.
Ⅳ．Discussion
 ESWT demonstrated a safety profile without 
complications and improved the JOA hip score and 
VAS, indicating ESWT can be an optional conservative 
treatment for advanced ONFH. However, ESWT did 
not improve the natural history of the osteonecrosis nor 
prevent an eventual THA. ESWT was first applied for 
ONFH in 1998［22］. In Japan, clinical use of ESWT 
was approved in 2008. Experimental work has indicated 
some palliative effect for ESWT［13-15］, although 
clinical trials are limited. Thus, the goal of our study 
was to evaluate its safety and effectiveness. ESWT 
Fig. 3　 Survivorship of stage 3B and stage 4 hips by 
JMHLW classification
　When the end point was total hip arthroplasty, survival 
at one year was 52.5% in stage 3B and 39.3% in stage 4; 
survival at two years was 48.8% in stage 3B and 13.5% in 
stage 4, with a significant difference （Kaplan-Meier and 
log rank test, p＝0.027）.
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hip by JMHLW was an independent prognostic factor 
for THA.
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